| Contents per vial | 10 mg |
|---|---|
| Form | Lyophilized powder |
| Packaging | Sealed glass vial |
| Purity | 99,94 % |
| Storage | 2–8 °C, keep dry and protect from light |
| Molecular formula | C50H68N14O10 |
| Molecular weight | 1025,16 g/mol |
| Sequence or structure | Ac–Nle–cyclo(Asp–His–D-Phe–Arg–Trp–Lys)–OH |
| CAS | 189691-06-3 |
| Intended use | For laboratory research only |
About this product
PT-141, known as bremelanotide, is a cyclic melanocortin peptide investigated for central regulation of sexual response. Unlike substances acting primarily on blood vessels, it affects melanocortin receptors in the nervous system. Research focuses on sexual motivation, arousal and melanocortin signaling.
What is PT-141 / BREMELANOTIDE?
PT-141 / BREMELANOTIDE is classified as a “synthetic peptide or peptide analog” and is being evaluated in scientific research in relation to areas such as sexual response, melanocortin system, neuroendocrine signaling. Attention is paid to its interaction with relevant receptors, enzymes or cellular pathways and subsequent changes in measurable laboratory parameters.
Mechanism of action under investigation
Bremelanotide activates melanocortin receptors, particularly MC4R and other subtypes in the CNS. The effect is centrally mediated and is not based only on local vasodilation.
MAIN AREAS OF RESEARCH
• Sexual response: Bremelanotide is being investigated for central mechanisms of sexual desire and arousal that are controlled by melanocortin signaling in the nervous system.
• Melanocortin system: The molecule activates melanocortin receptors, particularly MC4R, and is used to investigate their role in brain circuits associated with sexual response.
• Neuroendocrine signaling: Research is looking at the link between melanocortin pathways and other neural and hormonal signals that influence sexual behavior.
Research findings to date
Work to date with PT-141 / BREMELANOTIDE has focused on areas including sexual response, the melanocortin system, and neuroendocrine signaling. Research focuses on sexual motivation, arousal and melanocortin signaling.
With bremelanotide, known side effects from clinical use are mainly nausea, flushing, headache and transient increase in blood pressure.
